{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:23:20Z","timestamp":1785813800690,"version":"3.56.0"},"reference-count":35,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic hepatitis B (CHB) infection constitutes a leading cause of hepatocellular carcinoma (HCC) development. The identification of HCC risk factors and the development of prognostic risk scores are essential for early diagnosis and prognosis. The aim of this observational, retrospective study was to evaluate baseline risk factors associated with HCC in CHB. Six hundred thirty-two consecutive adults with CHB (n = 632) [median age: 46 (IQR: 24)], attending the outpatients\u2019 Hepatology clinics between 01\/1993\u201309\/2020 were evaluated. Core promoter mutations and cirrhosis-HCC (GAG-HCC), Chinese University-HCC (CU-HCC), risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B), Fibrosis-4 (FIB-4), and Platelet Age Gender\u2013HBV (PAGE-B) prognostic scores were calculated, and receiver operating curves were used to assess their prognostic performance. HCC was developed in 34 (5.38%) patients. In the multivariable Cox regression analysis, advanced age (HR: 1.086, 95% CI: 1.037\u20131.137), male sex (HR: 7.696, 95% CI: 1.971\u201330.046), alcohol abuse (HR: 2.903, 95% CI: 1.222\u20136.987) and cirrhosis (HR: 21.239, 95% CI: 6.001\u201375.167) at baseline were independently associated with the development of HCC. GAG-HCC and PAGE-B showed the highest performance with c-statistics of 0.895 (95% CI: 0.829\u20130.961) and 0.857 (95% CI: 0.791\u20130.924), respectively. In the subgroup of patients with cirrhosis, the performance of all scores declined. When treated and untreated patients were studied separately, the discriminatory ability of the scores differed. In conclusion, HCC development was independently associated with advanced age, male sex, alcohol abuse, and baseline cirrhosis among a diverse population with CHB. GAG-HCC and PAGE-B showed high discriminatory performance to assess the risk of HCC development in these patients, but these performances declined in the subgroup of patients with cirrhosis. Further research to develop scores more specific to certain CHB subgroups is needed.<\/jats:p>","DOI":"10.3390\/cancers16142521","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:16:57Z","timestamp":1720772217000},"page":"2521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Predictive Risk Factors and Scoring Systems Associated with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B"],"prefix":"10.3390","volume":"16","author":[{"given":"Ploutarchos","family":"Pastras","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaggelos","family":"Zazas","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kalafateli","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4489-1485","authenticated-orcid":false,"given":"Ioanna","family":"Aggeletopoulou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-5070","authenticated-orcid":false,"given":"Efthymios P.","family":"Tsounis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Kanaloupitis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6896-6974","authenticated-orcid":false,"given":"Konstantinos","family":"Zisimopoulos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini-Eleni-Konstantina","family":"Kottaridou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Antonopoulou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimosthenis","family":"Drakopoulos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Diamantopoulou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0552-9195","authenticated-orcid":false,"given":"Aggeliki","family":"Tsintoni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Thomopoulos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-8209","authenticated-orcid":false,"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"ref_1","unstructured":"(2018). European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_3","first-page":"88","article-title":"The changing epidemiology of hepatocellular carcinoma in Greece","volume":"35","author":"Markakis","year":"2022","journal-title":"Ann. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.jhepr.2021.100290","article-title":"Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B","volume":"3","author":"Papatheodoridis","year":"2021","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cnur.2019.02.004","article-title":"Diagnosis and Management of Hepatitis B and C","volume":"54","author":"Pardee","year":"2019","journal-title":"Nurs. Clin. N. Am."},{"key":"ref_8","unstructured":"CDC (2023, December 16). Hepatitis B FAQs for Health Professionals | CDC. Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/hepatitis\/hbv\/hbvfaq.htm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","article-title":"The diagnosis and treatment of hepatocellular carcinoma","volume":"34","author":"Hartke","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_10","first-page":"759","article-title":"Cirrhosis: Diagnosis and Management","volume":"100","author":"Smith","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sachar, Y., Brahmania, M., Dhanasekaran, R., and Congly, S.E. (2021). Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses, 13.","DOI":"10.3390\/v13071318"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8314","DOI":"10.3748\/wjg.v22.i37.8314","article-title":"Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients","volume":"22","author":"Lee","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jvh.12727","article-title":"Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score","volume":"24","author":"Brouwer","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kariyama, K., Nouso, K., Toyoda, H., Tada, T., Hiraoka, A., Tsuji, K., Itobayashi, E., Ishikawa, T., Wakuta, A., and Oonishi, A. (2019). Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11020203"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s11135-017-0584-6","article-title":"Confounding and collinearity in regression analysis: A cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour","volume":"52","author":"Johnston","year":"2018","journal-title":"Qual. Quant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/jvh.13402","article-title":"Meta-analysis: Association between hepatitis B virus preS mutation and hepatocellular carcinoma risk","volume":"28","author":"Wungu","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Torresi, J., Tran, B.M., Christiansen, D., Earnest-Silveira, L., Schwab, R.H.M., and Vincan, E. (2019). HBV-related hepatocarcinogenesis: The role of signalling pathways and innovative ex vivo research models. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5916-6"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4254\/wjh.v14.i4.708","article-title":"Review on hepatitis B virus precore\/core promoter mutations and their correlation with genotypes and liver disease severity","volume":"14","author":"Kumar","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Datfar, T., Doulberis, M., Papaefthymiou, A., Hines, I.N., and Manzini, G. (2021). Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens, 10.","DOI":"10.3390\/pathogens10111366"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Baglieri, J., Brenner, D.A., and Kisseleva, T. (2019). The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071723"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","article-title":"Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lyu, X., Liu, K., Chen, Y., Wang, Z., Yao, J., Cai, G., Jiang, Z., Wang, Z., Jiang, J., and Gu, H. (2016). Analysis of Risk Factors Associated with the Development of Hepatocellular Carcinoma in Chronic HBV-Infected Chinese: A Meta-Analysis. Int. J. Environ. Res. Public. Health, 13.","DOI":"10.3390\/ijerph13060604"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kaur, S.P., Talat, A., Karimi-Sari, H., Grees, A., Chen, H.W., Lau, D.T.Y., and Catana, A.M. (2022). Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg). J. Clin. Med., 11.","DOI":"10.3390\/jcm11041126"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/jac\/dku041","article-title":"Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B","volume":"69","author":"Hsu","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","first-page":"1073274817729240","article-title":"The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer","volume":"24","author":"Shiani","year":"2017","journal-title":"Cancer Control J. Moffitt Cancer Cent."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pandyarajan, V., Govalan, R., and Yang, J.D. (2021). Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020479"},{"key":"ref_31","unstructured":"Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M.A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., and Amoako, Y. (2017). The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol., 3, 1683\u20131691."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: A systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","author":"Wong","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"2023","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:35Z","timestamp":1760109335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":35,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142521"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142521","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}